CRNX Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.

Jefferies Global Healthcare Conference 2025

Company presentation: Thursday, June 5, 2025 at 12:50 p.m. Eastern Time

Webcast link:

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at .

If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

ABOUT CRINETICS PHARMACEUTICALS

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, , is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:

Gayathri Diwakar

Head of Investor Relations



(858) 345-6340

Media:

Natalie Badillo

Head of Corporate Communications



(858) 345-6075



EN
23/05/2025

Underlying

CRNXCrinetics Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Crinetics Pharmaceuticals

 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Unde...

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement ...

August 11, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Result...

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update       Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date       Continued Progress on the Global Development Program for Atumelnant Across Multiple Trials, Including the BALANCE-CAH Phase 2/3 Study for the Treatment of Children with Congenital Adrenal Hyperplasia Expected to Initiate this Year       $1.2B in Cash, Cash Equivalents, and Investment Securities as of June 30, 2...

August 7, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics to Present New Long-Term Data Demonstrating Durable Control ...

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies Additional PALSONIFY presentations demonstrate reductions in patient-reported symptom burden, including both symptom severity and rates of symptom flares SAN DIEGO, July 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced new data from its clinical development program e...

July 13, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Resu...

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 404-975-4839Access Code: 899803    Webcast: Participants can use the dial-in number...

July 11, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under ...

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit (“RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Pla...

July 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch